


Introduction to Statistics in Pharmaceutical Clinical Trials

Todd A Durham and J Rick Turner

The background of the cover is a complex, abstract composition of overlapping, semi-transparent geometric shapes and lines. The color palette is diverse, featuring deep blues, vibrant oranges, bright yellows, and rich reds. The shapes are primarily rectangular and triangular, creating a sense of depth and movement. The overall effect is a modern, data-driven aesthetic that complements the book's focus on statistics and clinical trials.

Introduction to Statistics in Pharmaceutical Clinical Trials

Introduction to Statistics in Pharmaceutical Clinical Trials

Todd A Durham MS

Senior Director of Biostatistics and Data Management
Inspire Pharmaceuticals
Durham, North Carolina, USA

J Rick Turner PhD

Chairman, Department of Clinical Research
Campbell University School of Pharmacy
Research Triangle Park, North Carolina, USA
and
Consulting Executive Director of Operations
CTMG, Inc.
Greenville and Wilson, North Carolina, USA

Published by the Pharmaceutical Press

An imprint of RPS Publishing

1 Lambeth High Street, London SE1 7JN, UK

100 South Atkinson Road, Suite 200, Greyslake, IL 60030-7820, USA

© J Rick Turner and Todd A Durham 2008

(PP) is a trade mark of RPS Publishing

RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain

First Published 2008

Typeset by J&L Composition, Filey, North Yorkshire

Printed in Great Britain by Cambridge University Press,
Cambridge

ISBN 978 0 85369 714 5

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder.

The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made.

The right of J Rick Turner and Todd A Durham to be identified as the authors of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

A catalogue record for this book is available from the British Library

Disclaimer

The drug selections and doses given in this book are for illustration only. The authors and publishers take no responsibility for any actions consequent upon following the contents of this book without first checking current sources of reference.

All doses mentioned are checked carefully. However, no stated dose should be relied on as the basis for prescription writing, advising or monitoring. Recommendations change constantly, and a current copy of an official formulary, such as the British National Formulary or the Summary of Product Characteristics, should always be consulted. Similarly, therapeutic selections and profiles of therapeutic and adverse activities are based upon the authors' interpretation of official recommendations and the literature at the time of publication. The most current literature must always be consulted.

Contents

Foreword x
Preface xii
Dedications xiv

1	The discipline of Statistics: Introduction and terminology	1
1.1	Introduction	1
1.2	The discipline of Statistics	2
1.3	The term “statistic” and the plural form “statistics”	3
1.4	The term “statistical analysis”	3
1.5	Association versus causation	3
1.6	Variation and systematic variation	4
1.7	Compelling evidence	4
1.8	The terms “datum” and “data”	5
1.9	Results from statistical analyses as the basis for decision-making	5
1.10	Blood pressure and blood pressure medication	5
1.11	Organization of the book	6
1.12	Some context before reading Chapters 2–11	7
1.13	Review	8
1.14	References	8
2	The role of clinical trials in new drug development	9
2.1	Introduction	9
2.2	Drug discovery	9
2.3	Regulatory guidance and governance	10
2.4	Pharmaceutical manufacturing	13
2.5	Nonclinical research	14
2.6	Clinical trials	15
2.7	Postmarketing surveillance	18
2.8	Ethical conduct during clinical trials	19
2.9	Review	20
2.10	References	20

3	Research questions and research hypotheses	23
3.1	Introduction	23
3.2	The concept of scientific research questions	23
3.3	Useful research questions	23
3.4	Useful information	24
3.5	Moving from the research question to the research hypotheses	24
3.6	The placebo effect	24
3.7	The drug treatment group and the placebo treatment group	25
3.8	Characteristics of a useful research question	25
3.9	The reason why there are two research hypotheses	26
3.10	Other forms of the null and alternate hypotheses	27
3.11	Deciding between the null and alternate hypothesis	28
3.12	An operational statistical definition of “more”	29
3.13	The concept of statistically significant differences	30
3.14	Putting these thoughts into more precise language	30
3.15	Hypothesis testing	31
3.16	The relationship between hypothesis testing and ethics in clinical trials	31
3.17	The relationship between research questions and study design	32
3.18	Review	33
3.19	References	33
4	Study design and experimental methodology	35
4.1	Introduction	35
4.2	Basic principles of study design	36
4.3	A common design in therapeutic exploratory and confirmatory trials	38
4.4	Experimental methodology	40
4.5	Why are we interested in blood pressure?	41
4.6	Uniformity of blood pressure measurement	43
4.7	Measuring change in blood pressure over time	43
4.8	The clinical study protocol	44
4.9	Review	45
4.10	References	45
5	Data, central tendency, and variation	47
5.1	Introduction	47
5.2	Populations and samples	47
5.3	Measurement scales	48
5.4	Random variables	49
5.5	Displaying the frequency of values of a random variable	49
5.6	Central tendency	52
5.7	Dispersion	53
5.8	Tabular displays of summary statistics of central tendency and dispersion	55

- 5.9 Review 56
- 5.10 References 56

6 Probability, hypothesis testing, and estimation 57

- 6.1 Introduction 57
- 6.2 Probability 57
- 6.3 Probability distributions 60
- 6.4 Binomial distribution 61
- 6.5 Normal distribution 62
- 6.6 Classical probability and relative frequency probability 67
- 6.7 The law of large numbers 68
- 6.8 Sample statistics and population parameters 69
- 6.9 Sampling variation 69
- 6.10 Estimation: General considerations 70
- 6.11 Hypothesis testing: General considerations 74
- 6.12 Hypothesis test of a single population mean 78
- 6.13 The p value 80
- 6.14 Relationship between confidence intervals and hypothesis tests 81
- 6.15 Brief review of estimation and hypothesis testing 82
- 6.16 Review 83
- 6.17 References 83

7 Early phase clinical trials 85

- 7.1 Introduction 85
- 7.2 A quick recap of early phase studies 85
- 7.3 General comments on study designs in early phase clinical studies 86
- 7.4 Goals of early phase clinical trials 86
- 7.5 Research questions in early phase clinical studies 87
- 7.6 Pharmacokinetic characteristics of interest 87
- 7.7 Analysis of pharmacokinetic and pharmacodynamic data 89
- 7.8 Dose-finding trials 91
- 7.9 Bioavailability trials 92
- 7.10 Other data acquired in early phase clinical studies 93
- 7.11 Limitations of early phase trials 94
- 7.12 Review 95
- 7.13 References 95

8 Confirmatory clinical trials: Safety data I 97

- 8.1 Introduction 97
- 8.2 The rationale for safety assessments in clinical trials 97
- 8.3 A regulatory view on safety assessment 98

8.4	Adverse events	99	
8.5	Reporting adverse events	99	
8.6	Using all reported AEs for all participants	100	
8.7	Absolute and relative risks of participants reporting specific AEs	101	
8.8	Analyzing serious AEs	102	
8.9	Concerns with potential multiplicity issues	102	
8.10	Accounting for sampling variation	103	
8.11	A confidence interval for a sample proportion	103	
8.12	Confidence intervals for the difference between two proportions	105	
8.13	Time-to-event analysis	107	
8.14	Kaplan–Meier estimation of the survival function	109	
8.15	Review	114	
8.16	References	115	
9	Confirmatory clinical trials: Safety data II		117
9.1	Introduction	117	
9.2	Analyses of clinical laboratory data	117	
9.3	Vital signs	123	
9.4	QT interval prolongation and torsades de pointes liability	124	
9.5	Concluding comments on safety assessments in clinical trials	125	
9.6	Review	126	
9.7	References	126	
10	Confirmatory clinical trials: Analysis of categorical efficacy data		127
10.1	Introduction: Regulatory views of substantial evidence	127	
10.2	Objectives of therapeutic confirmatory trials	130	
10.3	Moving from research questions to research objectives: Identification of endpoints	131	
10.4	A brief review of hypothesis testing	132	
10.5	Hypothesis tests for two or more proportions	133	
10.6	Concluding comments on hypothesis tests for categorical data	145	
10.7	Review	145	
10.8	References	146	
11	Confirmatory clinical trials: Analysis of continuous efficacy data		147
11.1	Introduction	147	
11.2	Hypothesis test of two means: Two-sample <i>t</i> test or independent groups <i>t</i> test	147	
11.3	Hypothesis test of the location of two distributions: Wilcoxon rank sum test	150	
11.4	Hypothesis tests of more than two means: Analysis of variance	152	

11.5	A worked example with a small dataset	155
11.6	A statistical methodology for conducting multiple comparisons	159
11.7	Bonferroni's test	160
11.8	Employing Bonferroni's test in our example	161
11.9	Tukey's honestly significant difference test	163
11.10	Implications of the methodology chosen for multiple comparisons	164
11.11	Additional considerations about ANOVA	166
11.12	Nonparametric analyses of continuous data	167
11.13	The Kruskal–Wallis test	167
11.14	Hypothesis test of the equality of survival distributions: Logrank test	169
11.15	Review	171
11.16	References	172
12	Additional statistical considerations in clinical trials	173
12.1	Introduction	173
12.2	Sample size estimation	173
12.3	Multicenter studies	181
12.4	Analysis populations	182
12.5	Dealing with missing data	184
12.6	Primary and secondary objectives and endpoints	185
12.7	Evaluating baseline characteristics	186
12.8	Equivalence and noninferiority study designs	187
12.9	Additional study designs	189
12.10	Review	190
12.11	References	190
13	Concluding comments	191
	Reference	191
	Appendices	193
	Appendix 1: Standard normal distribution areas	195
	Appendix 2: Percentiles of t distributions	205
	Appendix 3: Percentiles of χ^2 distributions	207
	Appendix 4: Percentiles of F distributions ($\alpha = 0.05$)	209
	Appendix 5: Values of q for Tukey's HSD test ($\alpha = 0.05$)	211
	Review exercise solutions by chapter	215
	Index	219

Foreword

With this introductory text, the authors have managed to de-mystify Statistics for students of pharmacy and clinical research who may be taking their first, or one of their earliest, courses in the subject. Three fundamental departures from the standard treatment of statistics are evident from the start – the way in which “Statistics” is defined, the organization of the book itself, and the use of a single, unifying disease area for illustration throughout the book. The reference to Statistics as “an experimental approach to gaining knowledge” at the start of the first chapter sets the tone for the rest of the book. Statistical concepts are defined and explained relative to their usefulness in clinical decision making. A unique operational definition of the discipline of Statistics is presented that consists of six components, beginning with the posing of a research question and concluding with both a regulatory submission and peer-reviewed publication. This is a far cry from the standard definitions used in most Statistics texts and alerts the reader to the fact that applications and discussions of utility will be intertwined with mathematical concepts and methodologies for the duration of their reading.

Rather than simply providing an exposition of mathematical terms and operators followed by a canvassing of the usual array of statistical tools and techniques, the authors choose instead to follow the product development pathway in organizing their book, showing how statistics plays an important role in providing the ability to move from step to step with objectivity and sound decision making. After an overview of the drug development paradigm that includes the nonclinical, manufacturing, and marketing aspects, the reader is introduced to the fundamentals of experimental design, probability dis-

tributions, and hypothesis testing. The reader is then guided through each phase of pharmaceutical clinical trials. From early phase to confirmatory trials, the questions that need to be addressed and the types of data and statistical tools needed to address them are explained and fully illustrated with an antihypertensive treatment example. Note, however, that the straightforward nature of the exposition does not equate to simplicity of subject matter. Nonparametric statistics, noninferiority trials, and adaptive designs all receive mention as the text covers the majority of situations these future researchers are likely to encounter. And unlike many basic statistics texts with a focus on efficacy occupying the majority of the pages, safety analyses receive nearly equal treatment here. Timely safety topics of particular clinical interest, such as QT/QTc interval prolongation and how to design a study to test for this adverse effect, are covered.

Focusing on a potential treatment of hypertension for illustration throughout the book provides consistency and really makes the product development pathway come alive. The reader has the sense of helping move this product from phase to phase, and the example serves to not only illustrate the statistical methods, but also the clinical decision making surrounding the product’s development. In addition, the reader is able to accumulate the medical background required to appreciate the data examples in a minimum number of pages, and the example is rich enough so as to not afford any loss of generality with this singular focus.

The dialogue between clinician and statistician is of the utmost importance in the successful execution of a product development program today. The need for strong communication skills, verbal and written, among those involved in this

complex process has never been greater. The authors have provided a text that fully equips students to engage in clear and meaningful dialogue with their clinical colleagues and regulatory counterparts. By focusing on the common goal of learning essential information about experimental products through well-designed and well-conducted studies, and accurately collected and appropriately analyzed data, the reader never loses sight of the fact that statistics are the means to the end, and not the end in themselves. As the authors note on page 191, “Our interest in Statistics, then, is a pragmatic one: The discipline provides the best way currently available to conduct clinical development programs.”

I have had the pleasure of working with Todd Durham for over 10 years and I am not surprised in the least with his clear and concise treatment of Statistics in this text. He is known among friends, colleagues, and students for his thoughtful approach to study design and analysis

problems, his excellent communication skills, and his great capacity for mentoring and tutoring others. His contributions through this text will enable other classrooms to benefit from his winning style of teaching even when he is not present to lead the discussion himself. Todd is an Adjunct Professor of Clinical Research at the Campbell University School of Pharmacy, and teaches Statistics to students in the Master of Science in Clinical Research program. I am delighted that this collaboration with Rick Turner, the Chairman of the Department of Clinical Research, has proved so successful.

Lisa M. LaVange, Ph.D.
Professor and Director, Collaborative
Studies Coordinating Center
Department of Biostatistics,
School of Public Health
University of North Carolina at Chapel Hill
Chapel Hill, NC, USA
January 2008

Preface

This book is an introductory statistics textbook designed primarily for students of pharmacy, clinical research, and allied health professions. It takes a novel approach by not only teaching you how to conduct individual statistical analyses, but also placing these analyses in the context of the clinical research activities needed to develop a new pharmaceutical drug. By taking this approach, we are able to provide you with a unified theme throughout the book and, in addition, to teach you the computational steps needed to conduct these analyses and provide you with a powerful conceptual understanding of why these analyses are so informative. This approach also makes the book well suited to professionals entering the pharmaceutical, biotechnology, and contract research organization (CRO) industries who wish to gain a broader understanding of study design and research methodology in clinical trials. Both target audiences will find this book a useful introduction to the central role of the discipline of Statistics in the clinical development of pharmaceutical drugs that improve the human condition. Important concepts are reinforced with review questions at the end of chapters.

By focusing on the statistical analyses most commonly used in drug development and employing an organizational structure that follows the order in which these statistical analyses are commonly used in clinical drug development, the book shows you how the discipline of Statistics facilitates the acquisition of optimum quality data, that is, numerical representations of relevant information, which form the basis of rational decision-making throughout the drug development process.

Although this book meaningfully integrates the computational aspects of statistics with the overall conceptual objectives for which they are

used, we have not included some topics that are traditionally included in introductory statistics textbooks, including linear regression and correlation. We believe that the selected topics and the depth at which they are discussed are appropriate and unique for our intended audience. While we are very happy with the title of the book as it is, the title *The Statistical Basis of Decision-making in Pharmaceutical Clinical Trials* would capture one of the book's major themes extremely well.

The motivation to write this book is directly related to our professional activities. Both of us teach Statistics in the Department of Clinical Research at the Campbell University School of Pharmacy (TD, a professional biostatistician, is also an Adjunct Professor of Clinical Research, and RT is Chairman of this department). The department is located in the heart of North Carolina's Research Triangle Park, one of the world's leading pharmaceutical and biotechnology research centers. Statistics courses in this department are therefore taught in the context of the development of new pharmaceutical and biopharmaceutical products, with the goal of providing a solid knowledge and understanding of the nature, methods, applications, and importance of the discipline of Statistics. It should be emphasized that we are not training our students to be professional statisticians. Rather, we wish them to become familiar with the basics of design, methodology, and analysis as used in the development of new drugs. We aim to convey the following information:

- why, and how, data are collected in clinical studies (to investigate a specific question, using appropriate study design and research methodology)

- how these data are summarized and analyzed (descriptive statistics, hypothesis testing and inferential statistics, statistical significance)
- what the results mean in the context of the clinical research question (interpretation, estimation, and clinical significance)
- how the results are communicated to regulatory agencies and to the scientific and medical communities.

By presenting statistical analysis in a meaningful, integrated, and relevant manner, our students' knowledge and retention of the material is markedly improved. Moreover, their understanding and appreciation of the discipline of Statistics in all of their future scientific endeavors (both academically while studying, and professionally once in the workforce) is considerably enhanced. This book will become the text for the first of two Statistics courses in our Master of Science in Clinical Research program.

It is appropriate to acknowledge here that neither author is a clinician. The first author is a professional statistician and the second a professional educator, medical writer, and research methodologist. We are also both clinical trialists: The first author is experienced in statistical aspects of clinical trials, and the second in writing regulatory clinical documentation. At various points throughout this book, we discuss how the discipline of Statistics provides the rational evidence for making clinical decisions. On several occasions we use hypothetical data, show how statistical analyses of these data and the associated statistical interpretations can form the rational basis for clinical decision-making, and illustrate what the hypothetical

clinical decision might be. This is done for educational purposes. Please remain aware, when reading our hypothetical clinical interpretations, that we are not clinicians: We are conveying the logic and importance of incorporating statistical information in the process of clinical decision-making. The crucial role that the discipline of Statistics plays in clinical practice is to provide the information upon which evidence-based clinical practice is based. The most effective drug development programs, one facet of the larger field of clinical research, result from the collaboration of many specialists, including statisticians and clinicians. Actual clinical decisions are, of course, the province of clinicians.

We express our thanks to professional colleagues and students who have supported and informed us during the preparation of this book. Christina De Bono and Kevin Tuley at Pharmaceutical Press have provided constant support and assistance throughout this project, and we are very grateful. Richard Zink provided detailed reviews of several drafts of the manuscript. Finally, our previous students have provided invaluable feedback on lecture material and initial drafts of this book.

Views expressed in this book are those of the authors and Turner Medical Communications LLC, and not necessarily those of Inspire Pharmaceuticals and/or the Campbell University School of Pharmacy.

Todd Durham and Rick Turner
Research Triangle Park, NC, USA
August 2007

Dedications

This book is dedicated to Heidi Durham and Karen Turner, who have been there for us every step of the way. We also thank Rachel, Daisy, Misty, and Mishadow for their wonderful companionship.